台灣臨床試驗主持人資料庫|TPIDB

問卷

問卷調查提醒

您好：邀請您填寫網站的問卷意見調查表，讓我們有更多優化及改進的方向，一起提升使用者體驗。

系統通知

此案目前為暫存狀態

編修至YYYY/MM/DD

不開放編輯功能

確認送出

我同意

請先勾選「我同意」

當您勾選「我同意」時，表示您已閱讀、了解並同意接受本「會員同意書及隱私權政策」內容

繁中 EN

TPIDB

TPIDB Outstanding PI Advanced Search 聯絡我們

繁中 EN

TPIDB Outstanding PI

TPIDB > Search Result

Search Result

請選擇要匯出的欄位

全選

Plan Title (TW)

Plan Title (EN)

Plan No

NCT No

Start Date

End Date

Trial Phase

ICD-9

ICD-10

Applicant

CRO (TW)

CRO (EN)

Trial Scale

Indication (TW)

Indication (EN)

Purpose (TW)

Purpose (EN)

Drug Name (TW)

Drug Name (EN)

ATC Code

Ingredient (TW)

Ingredient (EN)

Dose Type (TW)

Dose Type (EN)

Dose (TW)

Dose (EN)

Evaluation (TW)

Evaluation (EN)

Inclusions (TW)

Inclusions (EN)

Exclusions (TW)

Exclusions (EN)

Taiwan Quantity

Global Quantity

IIT

Hospital

Accept Qty

Contact Name (TW)

Contact Name (EN)

Contact Phone (TW)

Contact Phone (EN)

Contact Email (TW)

Contact Email (EN)

Co-PI

Modify Search

Find Division/Department

Find Hospital

All Location

All Division/Department

All Division/Department
Division of Internal Medicine
Division of Surgery
Division of Others

篩選

Developmental Phase

Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others

Trial Status

Not yet recruiting
Active
Completed

Recruitment Status

Not yet recruiting
Recruiting
Completed
Terminated
Stop recruiting
Suspended
Study ended

Trial scale

Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center

The expected start time interval of the test

Trial Applicant

Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization

Important Roles

Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None

Audit by Sponsors/CRO

Sponsors
CRO
None

Investigator-initiated trial(IIT)

Filters

洪仁宇

Recruiting

List

86Cases

2025-10-01 - 2035-01-20

Active

Condition/Disease
Test Drug

Participate Sites
6Sites

Recruiting6Sites

2024-07-17 - 2026-06-30

Phase II

Completed

Condition/Disease
Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-05-01 - 2023-10-30

Phase II

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis

Condition/Disease

Pulmonary Fibrosis
Test Drug

BMS-986278

Participate Sites
3Sites

Recruiting3Sites

2018-09-01 - 2022-03-31

Phase III

PONENTE: A multicenter, open-label, Phase 3b trial for adult patients with severe eosinophilic leukocyte asthma who are treated with high-dose corticosteroid inhalers, plus long-acting beta 2 agonists and oral corticosteroids for long-term treatment, to evaluate subcutaneously Efficacy and safety of 30 mg injection of Benralizumab for reducing oral corticosteroid dosage

Condition/Disease

Severe eosinophilic leukocyte asthma
Test Drug

Benralizumab

Participate Sites
8Sites

Recruiting8Sites

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

郭漢彬

Taipei Medical University Hospital

Division of Thoracic Medicine

2021-10-20 - 2023-11-02

Others

Condition/Disease
Test Drug

Participate Sites
1Sites

Recruiting1Sites

2019-04-01 - 2022-05-31

Phase III

A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.

Condition/Disease

idiopathic pulmonary fibrosis
Test Drug

GLPG1690 (G451990)

Participate Sites
5Sites

Recruiting4Sites

許超群

Kaohsiung Municipal Gangshan Hospital

未分科

李岡遠

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

1 Previous page 5 6 7 8 9

搜尋計畫列表下載細項

全部

試驗主持人
實際收案人數

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB